By Gemifys
A BMI in the “overweight” range but under 30 leaves a lot of people wondering whether GLP-1 medications are even an option for them, especially after seeing so much coverage focused on obesity treatment specifically. The honest answer is: it depends on more than the number on the BMI scale, and eligibility criteria are more nuanced than a simple cutoff.
What the approved eligibility criteria actually say
Per FDA labeling and manufacturer prescribing information for GLP-1 medications approved for chronic weight management (such as semaglutide/Wegovy and tirzepatide/Zepbound), the general eligibility framework is a BMI of 30 or greater (obesity), or a BMI of 27 or greater (overweight) combined with at least one weight-related health condition — such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. This is consistent with broader clinical guidance from bodies like the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which frames these medications as approved for obesity or overweight-with-comorbidity, not purely based on how many pounds someone wants to lose.
That means a BMI around 28 doesn’t automatically rule someone out — the more relevant question is whether there’s an accompanying weight-related health condition that a prescriber can document, which is exactly the kind of case-by-case clinical judgment a doctor is positioned to make.
Why “at maintenance is easy, deficit is hard” is worth mentioning to a provider
Difficulty sustaining a calorie deficit over time — even while being able to maintain weight — is a recognized and studied phenomenon, not a personal failing. Research on weight regulation, including work highlighted by the National Institutes of Health (NIH), points to physiological adaptations — including changes in hunger hormones and metabolic rate — that make sustained deficits harder for many people, independent of willpower. That context is useful to raise directly with a prescriber, since it speaks to medical necessity rather than preference.
What tends to help when discussing this with a doctor
A few things that may strengthen a conversation with a primary care provider or specialist, based on general clinical guidance:
Bring a full history of weight-management attempts, including diets, exercise programs, and how long a deficit was typically sustainable before regaining — this documents the “medically appropriate” case beyond BMI alone.
Ask specifically about related labs and conditions — blood pressure, A1c, cholesterol panel, and sleep — since any of these being outside normal range could support eligibility under the BMI-27-plus-comorbidity pathway.
Ask about insurance-specific criteria separately from FDA eligibility — insurers often layer additional requirements (such as documented diet/exercise attempts over a set period) on top of FDA approval criteria, so a medication can be FDA-appropriate for someone but still require a prior authorization process with the insurer.
A word on safety
GLP-1 medications are prescription drugs with real side effects and contraindications, and eligibility decisions — including dosing — should always be made by a licensed prescriber based on a full medical history, not self-directed. If a provider determines a GLP-1 isn’t appropriate, they may be able to point to other evidence-based options for sustainable weight management.
This article is for general educational purposes only and does not constitute medical advice. GLP-1 medications require a prescription and medical supervision — do not start, stop, or adjust any medication without consulting your prescriber.
